Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
$16.60
-$0.28(-2.60%)
At close: 4:00 PM EST
$16.60
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$5.15 - $17.32
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.64M
Market Cap
$1.37B
Enterprise Value$545.31M
Total Cash (Recent Filing)$268.04M
Total Debt (Recent Filing)$4.14M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 17, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding87,045,006
10 Day Avg. Volume1,187,610
30 Day Avg. Volume1,641,610
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue43.32
Enterprise Value/Gross Profit43.32
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$22.33Price Target Upside34.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Pipeline AdvancementsAnalyst recommends buying Immunome, Inc. stock due to strong pipeline advancements in cancer immunotherapy.
Strategic PartnershipsThe company's recent strategic partnerships are seen as a positive step towards expanding its research and development capabilities.
Technological InnovationAnalysts highlight the innovative technology platform of Immunome, Inc. as a key driver for future growth.
Bears Say
Efficacy And Safety ConcernsSkeptics question the reliability of smaller N, single-arm Phase 2 data and whether better efficacy can come without greater on-target toxicities.
Market VolatilityMarket volatility is noted as a risk factor that could impact Immunome, Inc.'s stock performance.
Regulatory HurdlesConcerns are raised about the potential regulatory hurdles Immunome, Inc. may face with upcoming product approvals.
Immunome News
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $5.15 and its highest was $17.32 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $1.37B.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Nov 17, 2025 which is in 19 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Aug 06, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.517 by $0.017.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.57.
How many shares outstanding does Immunome have?
Immunome has 87,045,006 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.517. Following the earnings report the stock price went down -5.641%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
Immunome Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.33 (34.52% Upside)
$22.33 (34.52% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 786.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.07%
12-Months-Change
Fundamentals
Return on Equity
-81.20%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Immunome
Immunome, Inc. (IMNM) is a biotechnology company focused on developing innovative antibody-based therapies for cancer and other serious diseases. Utilizing its proprietary discovery platform, the company identifies and develops therapeutic candidates derived from the immune response of patients. Immunome aims to address unmet medical needs by creating targeted treatments that harness the body's own immune system to combat disease.
IMNM Stock 12 Month Forecast
Average Price Target
$22.33
▲(34.52% Upside)
Technical Analysis
Ownership Overview
1.59% Insiders
23.89% Mutual Funds
0.01% Other Institutional Investors
63.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---